I’m pleased to have the opportunity to lead this innovative technology company which is pioneering minimally invasive cryoablation procedure in the breast cancer market.
PLEASANTON, Calif. (PRWEB) August 07, 2018
BJ Hardman, Chief Executive Officer, today announced the appointment of Richard A. Stark to assume the role of Sanarus Technologies President, effective immediately. Mr. Stark will lead all company operations and will apply his 20+ years of strategic development, marketing and sales experience in medical device toward finding new and innovative ways to advance market adoption, help customers, increase funding activities, and drive product utilization globally.
“I’m pleased to have the opportunity to lead this innovative technology company which is pioneering a minimally invasive cryoablation procedure in the breast cancer market,” said Mr. Stark. “I look forward to bringing this safe and effective procedure to patients around the globe.”
Mr. Stark’s recent role as Senior Vice President, General Manager at AngioDynamics, resulted in him being instrumental in the development and commercialization of the company’s oncology strategy. From 2008 to 2012, he served as Vice President of Sales and Marketing, General Manager for the company’s oncology/surgery division before being promoted in 2012 to Senior Vice President, General Manager. He has extensive experience in shaping corporate strategy and is skilled in all aspects of corporate startup, growth, and acquisition. Prior to his tenure at AngioDynamics, he was Vice President of US Sales for RITA Medical and was instrumental in the sale of the company to AngioDynamics. He has also held field sales positions at Woodside Biomedical and Arrow/Teleflex. Mr. Stark joined the Board of Directors of Sanarus Technologies in 2016, and has worked alongside Dr. Govindarajan “Raj” Narayanan, Charles Berolzheimer, Lee Story, Matt Nalipinski, Sharon Maher, Heather Simonsen and BJ Hardman.
“We are thrilled to have Rick Stark lead the Sanarus Technologies team,” said Mrs. Hardman, Chief Executive Officer and Chairman. “Rick has years of success in start-ups and large corporations, and we look forward to the leadership he brings as we continue to increase adoption of the Visica® 2 Treatment System.”
The Visica 2 Treatment System is a minimally invasive alternative to lumpectomy or mastectomy. The patented, FDA-cleared system utilizes extreme cold to immediately kill cancerous tumors in a doctor’s office. An ultrasound-guided probe is inserted into the tumor under local anesthetic. An ice ball forms concentrically around the tumor, killing it immediately and the clean margins are detected real time via ultrasound. In less than 30 minutes of procedure time, the tumor is completely destroyed with virtually no scarring or cosmetic damage. Compared to lumpectomy or mastectomy, the Visica 2 Treatment System significantly reduces overall healthcare costs associated with operating room based surgical procedures as it negates the need for the use of an operating room, surgical revisions, or breast reconstruction.
About Sanarus Technologies, Inc.
In 2001, the Visica® Treatment System was the first system available for cryoablation of breast fibroadenomas. Since then, our systems have been used to successfully treat thousands of patients. The System is FDA-cleared for the ablation of cancerous or malignant tissue and benign tumors. With Sanarus’ invention of liquid nitrogen-based cryoablation in 2006, the Visica 2 Treatment System has been used to treat cancer in cryoablation-assisted surgeries and cryoablation-only procedures in clinical trials. At Sanarus, we pride ourselves in developing innovative solutions for the nonsurgical treatment of breast tumors. We are a majority woman-owned business, headquartered in Pleasanton, CA, and all our products are manufactured in the USA. Find out more at http://www.sanarus.com.